Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. 2008

Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
Department of Blood Transfusion and Transplantation Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

BACKGROUND Transplant patients would benefit from reduction of immunosuppression providing that graft rejection is prevented. We have evaluated a number of immunological markers in blood of patients in whom tacrolimus was withdrawn after renal transplantation. The alloreactive precursor frequency of CD4+ and CD8+ T cells, the frequency of T cell subsets and the functional capacity of CD4+CD25+FoxP3+ regulatory T cells (Treg) were analyzed before transplantation and before tacrolimus reduction. In a case-control design, the results were compared between patients with (n = 15) and without (n = 28) acute rejection after tacrolimus withdrawal. RESULTS Prior to tacrolimus reduction, the ratio between memory CD8+ T cells and Treg was higher in rejectors compared to non-rejectors. Rejectors also had a higher ratio between memory CD4+ T cells and Treg, and ratios <20 were only observed in non-rejectors. Between the time of transplantation and the start of tacrolimus withdrawal, an increase in naive T cell frequencies and a reciprocal decrease of effector T cell percentages was observed in rejectors. The proportion of Treg within the CD4+ T cells decreased after transplantation, but anti-donor regulatory capacity of Treg remained unaltered in rejectors and non-rejectors. CONCLUSIONS Immunological monitoring revealed an association between acute rejection following the withdrawal of tacrolimus and 1) the ratio of memory T cells and Treg prior to the start of tacrolimus reduction, and 2) changes in the distribution of naive, effector and memory T cells over time. Combination of these two biomarkers allowed highly specific identification of patients in whom immunosuppression could be safely reduced.

UI MeSH Term Description Entries
D007107 Immune System The body's defense mechanism against foreign organisms or substances and deviant native cells. It includes the humoral immune response and the cell-mediated response and consists of a complex of interrelated cellular, molecular, and genetic components. Immune Systems,System, Immune,Systems, Immune
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D015166 Monitoring, Immunologic Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumor antigen and other markers (often by RADIOIMMUNOASSAY), studies of cellular or humoral immunity in cancer etiology, IMMUNOTHERAPY trials, etc. Immune Monitoring,Immunologic Monitoring,Immunosurveillance,Monitoring, Immune,Monitoring, Radioimmunologic,Monitoring, Immunological,Monitoring, Radioimmunological,Radioimmunologic Monitoring,Immunological Monitoring,Radioimmunological Monitoring

Related Publications

Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
January 1987, International archives of allergy and applied immunology,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
June 2002, Transplantation,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
January 2007, Drugs,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
February 1989, Transplantation proceedings,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
January 2001, Transplantation proceedings,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
June 2003, Transplantation,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
February 1977, Surgery,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
May 2014, Transplantation,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
August 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Ellen Kreijveld, and Hans J P M Koenen, and Bram van Cranenbroek, and Esther van Rijssen, and Irma Joosten, and Luuk B Hilbrands
August 2003, Journal of clinical pharmacology,
Copied contents to your clipboard!